Streetbeat News

Products Services

IMNM

Immunome has acknowledged Ayala Pharmaceuticals' announcement of completing enrollment in the Phase 3 RINGSIDE study for AL102, a treatment for desmoid tumors. Earlier this month, Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:17 pm

BFRI

Biofrontera Inc. (BFRI) has announced a significant restructuring of its supply agreement with Biofrontera AG, including a substantial reduction in the transfer price of Ameluz to Biofrontera AG. Additionally, control of all US clinical trials of Ameluz will transfer to Biofrontera Inc. effective June 1.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:16 pm

PRSO

Peraso Inc. (NASDAQ:PRSO) announced the EtherWave software package for its 60 GHz IEEE 802.11ad module products, offering cross-platform support for Android, Windows, and Linux. EtherWave enables efficient Ethernet data transport over USB without specific drivers, targeting AR/VR and tactical communications applications. Currently in pre-release testing, EtherWave is expected to be generally available for Android by Q2 2024. Positive feedback from beta-customers highlights nearly 2Gbps throughput and enhanced security features.

Portfolio Pulse from Happy Mohamed

February 20, 2024 | 1:15 pm

DOW

IP

KALU

Wall Street's most accurate analysts have provided their views on three high-dividend yielding stocks in the materials sector: International Paper Company (IP), Dow Inc. (DOW), and Kaiser Aluminum Corporation (KALU). These stocks offer dividend yields of 5.17%, 5.05%, and 4.66% respectively. Recent updates include IP's Q4 sales missing analyst consensus, Dow's completion of a green bond offering, and Kaiser Aluminum's upcoming financial results announcement.

Portfolio Pulse from Avi Kapoor

February 20, 2024 | 1:14 pm

BFRI

Biofrontera Inc. has announced a $16 million private placement, structured in two tranches of $8 million each, with the second tranche contingent on achieving certain milestones. This financing, in accordance with Nasdaq rules, is aimed at supporting the company's R&D activities and further commercial growth, facilitated by a recent restructuring of its supply agreement.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:14 pm

KTOS

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) has ordered nine Zeus 1 and Zeus 2 rocket motors for initial customer funded flights. These motors are part of Kratos' strategy to provide affordable, high-performance solid rocket motors (SRMs) for various missions, including hypersonic test and ballistic missile targets. The Zeus SRMs are designed to offer performance improvements, allowing for more frequent, faster, and farther flights at reduced costs. Kratos' investments in hypersonic systems like Erinyes and Dark Fury complement these SRMs, positioning the company as a key player in both launcher and flyer systems.

Portfolio Pulse from Happy Mohamed

February 20, 2024 | 1:14 pm

AOSL

Alpha and Omega Semiconductor has introduced the AOZ32063MQV, a 3-phase driver integrated circuit (IC) designed for brushless DC motor drive applications. This new IC features 100 percent duty cycle operation on the high side, an integrated bootstrap diode, adjustable deadtime, and multiple protection mechanisms, enhancing the efficiency and reliability of 3-phase BLDC motor drive designs.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:10 pm

SXTP

60 Degrees Pharmaceuticals, Inc. (60P) announced sponsorship of pre-clinical studies to investigate tafenoquine's efficacy against Candida spp, including the drug-resistant Candida auris. The studies, conducted by Monash University, aim to address the urgent need for effective treatments against this emerging pathogen in healthcare settings. Tafenoquine, an anti-malarial drug approved by the FDA in 2018, shows promise due to its unique mode of action. Results are expected by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:09 pm

RNAZ

TransCode Therapeutics has announced the publication of a U.S. patent application for 'Nanoparticles And Template Directed RIG-I Agonist Precursor Compositions And Uses Thereof For Cancer Therapy', marking a significant step in its cancer therapy research.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:08 pm

HRMY

Harmony Biosciences has been granted FDA Orphan Drug Designation for Pitolisant, a significant milestone that could enhance the company's market position and potentially lead to expedited development and approval processes for this drug.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:07 pm